TheEdgeResearch
Home / Stocks / TRAX

First Tracks Biotherapeutics Inc (TRAX)

NASDAQ Healthcare Biotechnology
$41.64 ▼ -6.34%
Market Cap
$1.75B
Sector
Healthcare
Industry
Biotechnology
Beta
3.37
52-Wk Range
14.72-54.78
CEO
Daniel R. Faga
Country
US
Currency
USD

First Tracks Biotherapeutics Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $41.64, down 6.34% on the session, giving a market capitalisation of $1.75B. On trailing twelve-month figures it carries a trailing P/E of -9.27, a net margin of 0.0%. Its beta of 3.37 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-9.27
Price / Sales
0.00
Price / Book
9.86
EV / EBITDA
-9.71
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.02
Current ratio
9.16
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
104
IPO date
2026-04-20
Headquarters
San Diego, CA, US
About First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Comparable companies

First Tracks Biotherapeutics Inc is most often compared with the following Healthcare names:

ACRSANABATTOCLYMELDNIMUXIMVTMLTXODTXSABS
More research on TRAX
TRAX technical analysis TRAX TheEdge Score Compare against peers
Open full interactive analysis & DCF →